Avid Bioservices Inc (CDMO)

[cjgaddy]

Which will break 1st? What order the rest?

* The PS+ Exosomes Program: esp. given UTSW’s Dr. Alan Schroit’s reputation; initial POC done/advancing via partnership. See: http://tinyurl.com/zbwr7cc

* Sunrise Biomarkers: #1=B2GPI, #2=Complement & IL-10 Pathways(12-7-26/IASLC delayed, “not done”, after prelim. abstract said, “Pts=193, within the 1st subgroup of N=104, a 2nd subgroup isolated: MOS 5.9=>12.5mos.”, #3=???. See http://tinyurl.com/jbv3ms5

* The MSK/Wolchok collab: incl. revelation by the new(2nd) AACR’17 MSK abstract stating, “PPHM’s PS-Targeting + Adoptive Tcell Transfer(ACT) Eliminates Advanced Tumors without Off-Target Toxicities”. Plus, Dr. Wolchok co-author of 5 AACR’17 Posters: 2 of the 5 are w/PPHM re: PS-Targeting. Only one other is with a biotech: Genocea Biosciences. The 4th is MSKCC ONLY, and the 5th is jointly w/Cedars-Sinai/LA. See: http://tinyurl.com/z47hb2s

* The Rutgers/R.Birge collab: ex: “PS Sensing by TAM Receptors (Tyro3, Axl, Mertk) Regulates AKT-dep. Chemoresistance & PD-L1 Expression”) - 2/9/17/AACR. See: http://tinyurl.com/h4gdke3

* The Duke/H.Lyerly collab: ex: “AntiPS + antiPD-L1 leads to greater anti-tumor responses in TNBC” - latest is 10-22-16/AACR I-O Conf. – see: http://tinyurl.com/zzryfok

* The MDA/JB.Fleming collab: ex: “PreClin. Eval of DNAtrix’s DNX2401+FhuBAVI(1N11) for Pancreatic Cancer - significantly inhibited tumor growth; further enhanced its anticancer activity; warrants further clinical evaluation...”, 1-30-17 AACR(Mol.Cancer). See: http://tinyurl.com/hov4hfb

* The ImmunoVaccine Inc. collab: “PS-Targeting Enhances Anti-Tumor Activity of DepoVax Tumor Vaccine” - per AACR’17 4-4-17 poster. See: http://tinyurl.com/jxfm3hb

* The AZN & NCCN clinical collabs: Sunrise Biomarkers adjusted?

* Continuing Avid expansion/revs-growth.

MORE ON PRE-CLIN. COLLABS HERE: http://tinyurl.com/gwa2gkn
.
.
.
= = = = = = = = = = = KNOWN UPCOMING EVENTS:
Feb27-Mar2/Avid Booth #816: BioProcess Intl. West, SanFran https://lifesciences.knect365.com/bpi-west PR: http://tinyurl.com/zbflrcf

~Mar8: FY'17Q3 (qe 1-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm

Mar14/Avid: Repligen Corp's "Driving Bioprocessing Efficiency Seminar", Carlsbad http://www.repligen.com/sandiego2017 PR: http://tinyurl.com/zbflrcf
...2:45pm: Dr. David Briggs (Avid Scientist), "Case study: Positive Impact of Pre-packed Columns in a Multi-product Mfg. Facility"

Apr1-5: AACR 2017, WashDC http://tinyurl.com/jxfm3hb (Abstract Summaries pub. 3-1-17)
...MSKCC+PPHM: 4-2-17/1pm #574, “PSTargeting+RAD+AntiPD1 Promotes Anti-Tumor Activity, Melanoma”
...MSKCC+PPHM: 4-3-17/8am #1651, “PSTargeting+Adoptive TCell Transfer (ACT) Elims. Adv. Tumors w/o Off-Target Toxicities, Melanoma” <=2nd Joint MemSloan/PPHM study, see: http://tinyurl.com/h3ylrku
...PPHM: 4-4-17/8am #3652, “PSTargeting+LAG3+AntiPD1 Significantly Enhances Anti-Tumor Activity, Triple- MBC”
...IMMUNOVACCINE+PPHM: 4-4-17/8am #3657, ”PSTargeting Enhances Anti-Tumor Activity of a Tumor Vaccine(DepoVax), HPV-Induced Tumor”
INTERESTING:
Mem. Sloan’s Dr. Jedd. Wolchok is co-author of 5 AACR’17 Posters. 2 of the 5 are w/PPHM re: PS-Targeting. Only one other is with a biotech: Genocea Biosciences. The 4th is MSKCC ONLY, and the 5th is jointly w/Cedars-Sinai/LA. This is presuming that I searched properly (I think I did): http://www.abstractsonline.com/pp8/#!/4292 .
PEREGRINE (Joint Mem.Sloan Kettering Wolchok Lab & PPHM):
1. 4-2-17 #574 “Phosphatidylserine Targeting Antibody in Combination with Tumor Radiation & Immune Checkpoint Blockade Promotes Anti-Tumor Activity in Mouse B16 Melanoma”
2. 4-3-17 #1651 “Targeting Phosphatidylserine in Combination With Adoptive T Cell Transfer Eliminates Advanced Tumors Without Off-Target Toxicities in a Melanoma Preclin. Model”
NON-PEREGRINE:
3.(MSK ONLY): 4-2-17 #874 “Lifting the iron curtain: Imaging cellular barriers to combination chelation-immune checkpoint therapy”
4.(MSK & Genocea Bio. http://www.genocea.com GNCA/$130mm MktCap) 4-2-17 #632 “Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a NSCLC patient”
5.(MSK & Cedars-Sinai/LA) 34-4-17 #4705 “CTLA4 blockade with HER2-directed therapy yields clinical benefit in women undergoing radiation therapy for HER2+ breast cancer brain metastases”

Apr10-12: Immune Profiling World Congress 2017, WashDC (part of “World Vaccine Congress 2017”) http://tinyurl.com/zlr5cyj
...4-11-17 12:10pm: Dr. Jeff Hutchins***(VP/PreClinRes.), “Increasing the Benefits of Immune Checkpoint Therapies Thru Increased Tumor Infiltrating Activated T-Cells”
***Note: 1-4-17: Dr. Hutchins left Peregrine to become CSO of Heat-Biologics.

??Jun2-6: ASCO 2017, Chicago https://am.asco.org (Abstracts: Titles/MidAPR, Full=May17)

Jun19-22/Avid Booth #1411: BIO Intl. Convention, SanDiego http://www.convention.bio.org/2017

~Jul13: FY'17Q4 (fye 4-30-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm